Geron Corporation (NASDAQ: GERN) stock is trading higher during the premarket in reaction to data publication from the IMbark Phase 2 trial of imetelstat for myelofibrosis (MF) in the Journal of Clinical Oncology.
The publication highlights the clinical benefits observed in the study, including symptom response and overall survival, as well as positive biomarker and bone marrow fibrosis assessments, in heavily pre-treated patients.
As stated in the paper, IMbark tested two imetelstat doses, and the 9.4 mg/kg dose every three weeks demonstrated clinical benefits.
In addition, the reductions in key driver mutations of the disease that were also correlated to clinical benefits suggest the disease-modifying activity of imetelstat.
"Targeting the underlying MF malignant clones differentiates imetelstat from other therapeutic agents currently in development for MF," said the lead author of the paper.
Currently, the company is conducting IMpactMF Phase 3 trial. It plans to enroll approximately 320 patients with Intermediate-2 or High-risk myelofibrosis who are refractory to prior treatment with a JAK inhibitor, also referred to as refractory MF.
The primary endpoint is overall survival. Key secondary endpoints include symptom response, spleen response, progression-free survival, complete response, partial response, clinical improvement, duration of response, safety, pharmacokinetics, and patient-reported outcomes.
IMpactMF is currently enrolling patients.
Price Action: GERN shares are up 31.9% at $1.86 during the premarket trading session on the last check Friday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.